You are currently viewing a new version of our website. To view the old version click .

Cancers, Volume 8, Issue 4

April 2016 - 9 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (9)

  • Article
  • Open Access
41 Citations
8,791 Views
9 Pages

A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission

  • Roisin E. O’Cearbhaill,
  • Govind Ragupathi,
  • Jianglong Zhu,
  • Qian Wan,
  • Svetlana Mironov,
  • Guangbin Yang,
  • Maria K. Spassova,
  • Alexia Iasonos,
  • Sara Kravetz and
  • Ouathek Ouerfelli
  • + 3 authors

22 April 2016

We conducted a phase I study in ovarian cancer patients to evaluate the safety and immunogenicity of a synthetic unimolecular pentavalent carbohydrate vaccine (Globo-H, GM2, sTn, TF, and Tn) supported on a peptide backbone, conjugated to keyhole limp...

  • Review
  • Open Access
146 Citations
21,330 Views
22 Pages

KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment

  • Daniel Zeitouni,
  • Yuliya Pylayeva-Gupta,
  • Channing J. Der and
  • Kirsten L. Bryant

18 April 2016

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers with a dismal 7% 5-year survival rate and is projected to become the second leading cause of cancer-related deaths by 2020. KRAS is mutated in 95% of PDACs and is a well-validated...

  • Article
  • Open Access
6 Citations
6,612 Views
8 Pages

1 April 2016

We previously developed a new enzyme-targeting radiosensitization treatment named Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), which contains hydrogen peroxide and sodium hyaluronate for injection into various type...

  • Review
  • Open Access
47 Citations
9,272 Views
28 Pages

Radioresistance of Brain Tumors

  • Kevin Kelley,
  • Jonathan Knisely,
  • Marc Symons and
  • Rosamaria Ruggieri

30 March 2016

Radiation therapy (RT) is frequently used as part of the standard of care treatment of the majority of brain tumors. The efficacy of RT is limited by radioresistance and by normal tissue radiation tolerance. This is highlighted in pediatric brain tum...

  • Review
  • Open Access
91 Citations
10,757 Views
16 Pages

29 March 2016

Head and neck squamous cell carcinoma (HNSCC) is a highly heterogeneous disease that is the result of tobacco and/or alcohol abuse or infection with high-risk Human papillomaviruses. Despite the fact that HPV positive HNSCC cancers form a distinct cl...

  • Article
  • Open Access
26 Citations
6,609 Views
9 Pages

Differential miRNA-Expression as an Adjunctive Diagnostic Tool in Neuroendocrine Tumors of the Lung

  • Melanie Demes,
  • Christoph Aszyk,
  • Holger Bartsch,
  • Joachim Schirren and
  • Annette Fisseler-Eckhoff

25 March 2016

Pulmonary malignancies with neuroendocrine differentiation represent a rare subclass of lung carcinomas, which vary in the extent of differentiation and grade of biological aggressiveness. In particular, neuroendocrine tumors are classified into well...

  • Review
  • Open Access
69 Citations
14,572 Views
15 Pages

Mitochondrial Redox Signaling and Tumor Progression

  • Yuxin Chen,
  • Haiqing Zhang,
  • Huanjiao Jenny Zhou,
  • Weidong Ji and
  • Wang Min

25 March 2016

Cancer cell can reprogram their energy production by switching mitochondrial oxidative phosphorylation to glycolysis. However, mitochondria play multiple roles in cancer cells, including redox regulation, reactive oxygen species (ROS) generation, and...

  • Article
  • Open Access
10 Citations
5,386 Views
9 Pages

NORE1A Regulates MDM2 Via β-TrCP

  • M. Lee Schmidt,
  • Diego F. Calvisi and
  • Geoffrey J. Clark

23 March 2016

Mouse Double Minute 2 Homolog (MDM2) is a key negative regulator of the master tumor suppressor p53. MDM2 regulates p53 on multiple levels, including acting as an ubiquitin ligase for the protein, thereby promoting its degradation by the proteasome....

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Cancers - ISSN 2072-6694Creative Common CC BY license